HC Wainwright Issues Optimistic Estimate for SGMT Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – HC Wainwright lifted their Q1 2026 earnings estimates for Sagimet Biosciences in a report issued on Friday, May 1st. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.45) for the quarter, up from their prior forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at $0.81 EPS and FY2030 earnings at $2.33 EPS.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings results on Wednesday, March 11th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14.

A number of other research analysts have also weighed in on SGMT. Oppenheimer reissued an “outperform” rating on shares of Sagimet Biosciences in a research report on Friday. Canaccord Genuity Group raised their price target on shares of Sagimet Biosciences from $28.00 to $49.00 and gave the company a “buy” rating in a research report on Monday. Barclays started coverage on shares of Sagimet Biosciences in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price target on the stock. Rodman & Renshaw initiated coverage on shares of Sagimet Biosciences in a research report on Thursday, March 26th. They set a “buy” rating and a $28.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Tuesday, April 21st. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.63.

Sagimet Biosciences Price Performance

SGMT opened at $7.90 on Tuesday. The company’s 50-day moving average is $5.69 and its 200 day moving average is $6.28. Sagimet Biosciences has a fifty-two week low of $3.08 and a fifty-two week high of $11.41. The firm has a market capitalization of $257.38 million, a P/E ratio of -5.03 and a beta of 3.60.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its position in Sagimet Biosciences by 819.2% during the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Sagimet Biosciences during the 4th quarter valued at $30,000. Wedmont Private Capital purchased a new position in Sagimet Biosciences during the 4th quarter valued at $60,000. Virtu Financial LLC purchased a new position in Sagimet Biosciences during the 4th quarter valued at $62,000. Finally, Hamilton Lane Advisors LLC purchased a new position in Sagimet Biosciences during the 4th quarter valued at $66,000. 87.86% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Sagimet Biosciences

In other news, CEO David Happel sold 12,101 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total value of $64,861.36. Following the completion of the sale, the chief executive officer directly owned 677,621 shares in the company, valued at approximately $3,632,048.56. The trade was a 1.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.70% of the stock is currently owned by insiders.

Trending Headlines about Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright materially raised near‑term EPS forecasts across Q1–Q4 2026 and lifted FY2026–FY2030 estimates, trimming expected losses in 2026 and projecting positive earnings by FY2029–FY2030; the firm reiterates a “Buy” rating and a $29 price target, signaling improved analyst confidence in Sagimet’s pathway to profitability. HC Wainwright note (MarketBeat)
• Positive Sentiment: Canaccord Genuity raised its price target sharply from $28 to $49 and kept a “Buy” rating — a large upward revision that can attract momentum buyers and re-rate valuation expectations if the market accepts the new target. Canaccord target raise (Benzinga)
• Neutral Sentiment: HC Wainwright’s model still forecasts near‑term losses (FY2026 and FY2027 projected negative EPS) even as longer‑range years turn profitable; this implies investor gains depend on execution, trial/regulatory milestones or commercial progress that justify the out‑year upside. HC Wainwright note (MarketBeat)
• Negative Sentiment: Risk factors remain: the stock has a high beta (3.6) and a negative trailing PE, indicating volatility and continued losses — investors should weigh elevated price‑target optimism against execution risk and typical biotech binary outcomes.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.